# A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)

> **NCT01006980** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 675 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Vemurafenib
- **DRUG:** Dacarbazine

## Key facts

- **NCT ID:** NCT01006980
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-12
- **Final completion:** 2015-07
- **Target enrollment:** 675 (ACTUAL)
- **Last updated:** 2016-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01006980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01006980, "A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01006980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*